Revolution Medicines Inc — Balance Sheet (NASDAQ:RVMD) | MetaTrader

Open full chart

Financials

Overview 明細書 Statistics Dividends

Quarterly Annual

Total assets 567.4 M737.99 M811.93 M2.06 B2.56 B2.35 B Total liabilities 92.72 M135.42 M126.74 M235.51 M293.1 M723.21 M Total equity 474.68 M602.57 M685.19 M1.83 B2.27 B1.63 B Total liabilities & shareholders' equities 567.4 M737.99 M811.93 M2.06 B2.56 B2.35 B Total debt —————— Net debt ——————

ニュース

UBSがRevolution株をRAS阻害剤の潜在力を評価し買い推奨でカバレッジ開始

UBS assumes coverage on Revolution stock with buy rating on RAS inhibitor potential

Stifelがタンゴ・セラピューティクス株の投資判断をBuyで継続

RVMD Reports Wider-Than-Expected Q4 Loss, Issues 2026 Expense View

パイパー・サンドラー、医薬品への信頼感からRevolution株の目標株価を引き上げ

Piper Sandler raises Revolution stock price target on drug confidence

Needham、コスト増加を理由にRevolution Medicines株の目標株価を145ドルに引き下げ

Needham lowers Revolution stock price target to $145 on higher costs

Wells Fargo、臨床試験の進展を受けてRevolution株の目標株価を引き上げ

Wells Fargo raises Revolution stock price target on trial progress

Revolution Medicines, Inc. (RVMD) Q4 2025 Earnings Call Transcript

Revolution Medicines in spotlight as earnings loom after M&A chatter